Projected top future IBD drugs based on expected 2022 revenue

Top future inflammatory bowel disease drugs by expected 2022 revenue (in million U.S. dollars)

by Statista Research Department, last edited Aug 1, 2014
Projected top future IBD drugs based on expected 2022 revenue This statistic displays a projection of the top future inflammatory bowel disease drugs based on expected 2022 revenues worldwide. During this time, Janssen's Stelara, a therapy targeting Crohn's disease with expected approval in 2015, is expected to generate 399.5 million U.S. dollars in 2022 revenues. Approximately, 1 to 1.3 million people currently suffer from IBD in the United States, however, the cause of IBD is currently unknown. IBD occurs in the colon and intestine and can also impact other parts of the body.
Show more

Top future inflammatory bowel disease drugs by expected 2022 revenue (in million U.S. dollars)

Statista Accounts: Access All Statistics. Starting from $588 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.

Premium Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references

$49 / Month *

Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract.
   Prices do not include sales tax.
Leading companies trust Statista:
paypalgoogleadobepgsamsungtelekom
I think of Statista as Google for researchers. Statista provides you with the information you search for right away.
Dr. Horst Stipp

Dr. Horst Stipp
EVP, Research & Innovation, Advertising Research Foundation

Statistics on "Inflammatory bowel disease (IBD) in the U.S. "
  • Overview
The most important statistics
  • Prevalence
  • Hospitalizations
  • Treatment
  • Miscellaneous
Discover Statista
Need help with using Statista for your research? Tutorials and first steps
Further Content: Statistics, Studies, and Topic Pages
Learn more about how Statista can support your business.
Do you have any questions about our business solutions?

We provide you with detailed information about our Corporate Account.